发明授权
EP0837696B1 IMPROVED DELIVERY OF DIAGNOSTIC AND THERAPEUTIC AGENTS TO A TARGET SITE
失效
到目的地的诊断和治疗物质的改进的通讯
- 专利标题: IMPROVED DELIVERY OF DIAGNOSTIC AND THERAPEUTIC AGENTS TO A TARGET SITE
- 专利标题(中): 到目的地的诊断和治疗物质的改进的通讯
-
申请号: EP96918023.1申请日: 1996-06-07
-
公开(公告)号: EP0837696B1公开(公告)日: 2010-02-24
- 发明人: GRIFFITHS, Gary, L. , HANSEN, Hans, J. , GOVINDAN, Serengulam V.
- 申请人: Immunomedics, Inc.
- 申请人地址: 300 American Road Morris Plains, NJ 07950 US
- 专利权人: Immunomedics, Inc.
- 当前专利权人: Immunomedics, Inc.
- 当前专利权人地址: 300 American Road Morris Plains, NJ 07950 US
- 代理机构: Bohmann, Armin K.
- 优先权: US486166 19950607
- 国际公布: WO1996040245 19961219
- 主分类号: A61K47/48
- IPC分类号: A61K47/48 ; A61K51/10 ; A61P35/00 ; A61P9/00 ; A61P31/00 ; A61P37/06 ; A61P29/00 ; A61K39/395 ; A61K41/00
摘要:
An in vivo method for delivering a diagnostic or therapeutic agent to a target site in a mammal, wherein a targeting species including a targeting moiety and a diagnostic or therapeutic agent or a binding site for a subsequently administered diagnostic or therapeutic agent conjugate, the targeting moiety having a primary binding site whereby it specifically binds to the target, is administered and allowed to accrete at the target site, is improved by injecting into the circulatory system of the mammal a clearing agent that binds to the primary binding site of the targeting species, whereby non-localized primary targeting species is cleared from circulation. The method is especially useful in pretargeting methods because the clearing agent does not remove the primary targeting species or block secondary binding sites of the primary targeting species.
信息查询